Category

• Pipeline3

Organizations

• Bausch + Lomb59
• Eyes On Eyecare41
• Alcon, Inc.37
• American Optometric Association32
• Glaukos25
• Harrow25
• Aldeyra Therapeutics19
• Regeneron19
• Coopervision18
• Sight Sciences18

Tags

• IOP3
• Eye Drop Solution3
• Eye Drops3
• Glaucoma3
• Ocular Hypertension2
• Clinical Trials2
• Glaucoma Medications2
• Finance1
• Finances1

• Organizations: Qlaris Bio✕

Clear all

Pipeline

Qlaris Bio developing fixed-dose latanoprost and QLS-111 eye drop for glaucoma

New combination therapy involving the prostaglandin analog targets lowering episcleral venous pressure to lower IOP.

Pipeline

Positive data reported in Qlaris Bio's phase 2 POAG and OHT trials

QLS-111 ophthalmic formulation found to lower IOP by reducing episcleral venous pressure, demonstrating an additive effect when used with latanoprost.

Pipeline

Qlaris Bio raises $24M in financing for IOP-lowering glaucoma candidate

Latest funding supports ongoing clinical development of IOP-lowering therapeutic formulated to reduce episcleral venous pressure.